ARTELO BIOSCIENCES INC (ARTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.04-2.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARTL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ARTL — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-08-27
Material Modification to Rights of Security Holders. The information set forth in
Why it matters: Legal problems can hurt operations and finances. A fix may boost investor trust.
Watch forA settlement or good ruling in the case with Craft Capital Management has been announced.
Also watch forMore legal actions or bad results in the arbitration case.
Why it matters: This program is key for raising funds to support operations amid negative cash flow.
Supportive ifA press release confirming the successful sale of shares under the ATM program.
Worry ifNo updates or sales have been reported under the ATM program for two months.
Why it matters: Progress in ART26.12 could mean better options for treating pain without opioids.
Supportive ifManagement gives a timeline or good update on ART26.12's clinical trials.
Worry ifNo updates or bad news about ART26.12's development.
Why it matters: Progress on ART27.13 could signal potential revenue and validate the clinical pipeline. This is key for investor confidence.
Supportive ifManagement shares news about a partnership deal or big progress in talks.
Worry ifNo news or bad updates about ART27.13 partnership talks.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$291 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,338 loss on $10,000 · 13.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,373 loss on $10,000 · 93.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Raising money is key for funding operations and clinical trials.
Supportive ifNews of successful equity or debt offerings that raise a lot of capital.
Worry ifNot getting money can cause problems or delays.
Why it matters: The reverse stock split aims to boost share price and improve marketability. This could affect investor perception and liquidity.
Supportive ifShares begin trading on a split-adjusted basis at or above $1 per share.
Worry ifShares trade below $1 per share after the split.
Why it matters: Better cash flow shows that the company is managing losses well. This means better financial health.
Supportive ifQ2 earnings report shows cash flow from operations improving to less negative than -$3M.
Worry ifThe Q2 earnings report shows cash flow from operations is worse or below -$3M.
Why it matters: Good results would show the drug can help treat cancer anorexia-cachexia syndrome.
Supportive ifManagement shares good interim results from the Phase 2 study of ART27.13.
Worry ifThe Phase 2 study results are not good or show no real improvement.
Why it matters: Maintaining compliance with Nasdaq is crucial for listing stability. Non-compliance could lead to delisting risks.
Watch forNasdaq says it still meets listing rules.
Also watch forNasdaq issues a warning or delisting notice.
Why it matters: Ongoing legal problems could hurt Artelo's focus and financial health.
Worry ifThe legal claims against Artelo are resolved or settled.
Less concerning ifNew legal problems come up or current claims get worse.
Why it matters: Legal problems can hurt operations and finances. Solving them may help investor feelings.
Watch forGood news on legal issues or settlements reached.
Also watch forNew legal problems come up or current issues get worse.
Why it matters: The company needs money because it has negative cash flows. New funds can help.
Supportive ifNew financing deals for equity or debt over $1M are announced.
Worry ifNo new financing announcements over the next quarter.
Why it matters: Losing more money could mean bigger financial problems. This impacts cash flow and investor feelings.
Worry ifOperating losses exceed -$2.5M in Q3 2026.
Less concerning ifOperating losses improve or stay below -$2.5M in Q3 2026.